MNPR
Monopar Therapeutics
NASDAQ · Healthcare · Biotechnology · US
$71.47
+3.18%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -6.9%
- EBIT
- -15.8%
- EPS
- -30.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -83.0%
- EPS
- -99.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- +12.0%
- EBIT
- -3.4%
- Net income
- +12.0%
- EPS
- -36.0%
- Free cash flow
- -90.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026